Kyntra Bio
KYNB
66 hedge funds and large institutions have $426M invested in Kyntra Bio in 2014 Q4 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$64.2M |
| 2 |
SC
Sculptor Capital
New York
|
+$33.9M |
| 3 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$30.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.2M |
Top Sellers
KYNB Hedge Fund Activity: Q4 2014 in Review
66 of the 3,764 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2014, worth a combined $426M.
Buyers outnumbered sellers: 66 funds opened new KYNB positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $64.2M.
- 66 institutional investors held Kyntra Bio (KYNB) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $426M of Kyntra Bio stock for Q4 2014.
- 66 funds opened new Kyntra Bio positions in Q4 2014 and 0 closed out, a net change of +66 holders.
- The largest Kyntra Bio buyer in Q4 2014 was Adage Capital Partners, an estimated $64.2M added.
Based on aggregated 13F filings for Q4 2014.